APAC Stem Cell Therapy Market - Industry Trends and Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION 19

• 1.1 OBJECTIVES OF THE STUDY 19
• 1.2 MARKET DEFINITION 19
• 1.3 OVERVIEW OF THE ASIA PACIFIC STEM CELL THERAPY MARKET 20
• 1.4 CURRENCY AND PRICING 22
• 1.5 LIMITATIONS 22
• 1.6 MARKETS COVERED 22

2 ASIA PACIFIC STEM CELL THERAPY MARKET: SEGMENTATION 24

• 2.1 MARKETS COVERED 24
• 2.2 GEOGRAPHICAL SCOPE 25
• 2.3 YEARS CONSIDERED FOR THE STUDY 26
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
• 2.6 MULTIVARIATE MODELLING 31
• 2.7 PRODUCT SEGMENT LIFELINE CURVE 31
• 2.8 DBMR MARKET POSITION GRID 32
• 2.9 VENDOR SHARE ANALYSIS 34
• 2.10 MARKET END USER COVERAGE GRID 35
• 2.11 SECONDARY SOURCES 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 41

• 4.1 PESTEL 42
• 4.2 PORTER'S FIVE FORCES MODEL 43

5 EPIDEMIOLOGY 44

6 PIPELINE ANALYSIS FOR THE ASIA PACIFIC STEM CELL THERAPY MARKET 45

7 ASIA PACIFIC STEM CELL THERAPY MARKET: REGULATIONS 46

8 MARKET OVERVIEW 49

• 8.1 DRIVERS 51
  • 8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 51
  • 8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 52
  • 8.1.3 GROWING BIOTECHNOLOGY SECTOR 53
  • 8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 54
  • 8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 54
• 8.2 RESTRAINTS 55
  • 8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 55
  • 8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 55
  • 8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 56
  • 8.2.4 AVAILABILITY OF ALTERNATIVES 56
• 8.3 OPPORTUNITIES 57
  • 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 57
  • 8.3.2 RISE IN HEALTHCARE EXPENDITURE 57
  • 8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 58
• 8.4 CHALLENGES 58
  • 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 58
  • 8.4.2 STRINGENT REGULATIONS 59

9 ASIA PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE 61

• 9.1 OVERVIEW 62
• 9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 65
• 9.3 PLACENTAL/UMBILICAL STEM CELL 65
• 9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 66
• 9.5 OTHERS 67

10 ASIA PACIFIC STEM CELL THERAPY MARKET, BY TYPE 69

• 10.1 OVERVIEW 70
• 10.2 ALLOGENEIC STEM CELL THERAPY 73
  • 10.2.1 MUSCULOSKELETAL DISORDERS 74
  • 10.2.2 WOUNDS AND INJURIES 74
  • 10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 74
  • 10.2.4 SURGERIES 74
  • 10.2.5 GASTROINTESTINAL DISEASES 74
  • 10.2.6 OTHER APPLICATION 74
• 10.3 AUTOLOGOUS STEM CELL THERAPY 74
  • 10.3.1 CARDIOVASCULAR DISEASES 76
  • 10.3.2 GASTROINTESTINAL DISEASES 76
  • 10.3.3 OTHER APPLICATION 76

11 ASIA PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION 77

• 11.1 OVERVIEW 78
• 11.2 MUSCULOSKELETAL DISORDERS 80
• 11.3 WOUNDS AND INJURIES 81
• 11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 82
• 11.5 SURGERIES 83
• 11.6 GASTROINTESTINAL DISEASES 84
• 11.7 CARDIOVASCULAR DISEASES 84
• 11.8 OTHER APPLICATION 85

12 ASIA PACIFIC STEM CELL THERAPY MARKET, BY END USER 87

• 12.1 OVERVIEW 88
• 12.2 HOSPITAL AND SURGICAL CENTERS 91
• 12.3 THERAPEUTIC COMPANIES 91
• 12.4 SERVICES COMPANIES 92
• 12.5 OTHERS 93

13 ASIA PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 94

• 13.1 OVERVIEW 95
• 13.2 DIRECT TENDER 99
• 13.3 THIRD PARTY DISTRIBUTORS 99

14 ASIA PACIFIC STEM CELL THERAPY MARKET, BY REGION 101

• 14.1 ASIA-PACIFIC 102
  • 14.1.1 SOUTH KOREA 108
  • 14.1.2 JAPAN 110
  • 14.1.3 INDIA 112

15 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 114

• 15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 114

16 SWOT ANALYSIS 115

17 COMPANY PROFILE 116

• 17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 116
  • 17.1.1 COMPANY SNAPSHOT 116
  • 17.1.2 REVENUE ANALYSIS 116
  • 17.1.3 COMPANY SHARE ANALYSIS 117
  • 17.1.4 PRODUCT PORTFOLIO 117
  • 17.1.5 RECENT DEVELOPMENT 117

• 17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 118
  • 17.2.1 COMPANY SNAPSHOT 118
  • 17.2.2 REVENUE ANALYSIS 118
  • 17.2.3 COMPANY SHARE ANALYSIS 119
  • 17.2.4 PRODUCT PORTFOLIO 119
  • 17.2.5 RECENT DEVELOPMENTS 119
• 17.3 ORTHOFIX MEDICAL INC. (2021) 120
  • 17.3.1 COMPANY SNAPSHOT 120
  • 17.3.2 REVENUE ANALYSIS 120
  • 17.3.3 COMPANY SHARE ANALYSIS 121
  • 17.3.4 PRODUCT PORTFOLIO 121
  • 17.3.5 RECENT DEVELOPMENTS 121
• 17.4 MEDIPOST (2021) 123
  • 17.4.1 COMPANY SNAPSHOT 123
  • 17.4.2 REVENUE ANALYSIS 123
  • 17.4.3 COMPANY SHARE ANALYSIS 124
  • 17.4.4 PRODUCT PORTFOLIO 124
  • 17.4.5 RECENT DEVELOPMENTS 124
• 17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 126
  • 17.5.1 COMPANY SNAPSHOT 126
  • 17.5.2 REVENUE ANALYSIS 126
  • 17.5.3 COMPANY SHARE ANALYSIS 127
  • 17.5.4 PRODUCT PORTFOLIO 127
  • 17.5.5 RECENT DEVELOPMENT 127
• 17.6 CORESTEM, INC. (2021) 128
  • 17.6.1 COMPANY SNAPSHOT 128
  • 17.6.2 REVENUE ANALYSIS 128
  • 17.6.3 PRODUCT PORTFOLIO 129
  • 17.6.4 RECENT DEVELOPMENT 129
• 17.7 PHARMICELL CO., LTD. (2021) 130
  • 17.7.1 COMPANY SNAPSHOT 130
  • 17.7.2 PRODUCT PORTFOLIO 130
  • 17.7.3 RECENT DEVELOPMENTS 130
• 17.8 ANTEROGEN.CO., LTD (2021) 131
  • 17.8.1 COMPANY SNAPSHOT 131
  • 17.8.2 PRODUCT PORTFOLIO 131
  • 17.8.3 RECENT DEVELOPMENTS 131

• 17.9 ATHERSYS, INC.(2021) 132
  • 17.9.1 COMPANY SNAPSHOT 132
  • 17.9.2 REVENUE ANALYSIS 132
  • 17.9.3 PRODUCT PORTFOLIO 133
  • 17.9.4 RECENT DEVELOPMENTS 133
• 17.10 BRAINSTORM CELL LIMITED (2021) 134
  • 17.10.1 COMPANY SNAPSHOT 134
  • 17.10.2 PRODUCT PORTFOLIO 134
  • 17.10.3 RECENT DEVELOPMENTS 134
• 17.11 BIORESTORATIVE THERAPIES, INC. (2021) 136
  • 17.11.1 COMPANY SNAPSHOT 136
  • 17.11.2 REVENUE ANALYSIS 136
  • 17.11.3 PRODUCT PORTFOLIO 137
  • 17.11.4 RECENT DEVELOPMENTS 137
• 17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 138
  • 17.12.1 COMPANY SNAPSHOT 138
  • 17.12.2 PRODUCT PORTFOLIO 138
  • 17.12.3 RECENT DEVELOPMENTS 138
• 17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 140
  • 17.13.1 COMPANY SNAPSHOT 140
  • 17.13.2 REVENUE ANALYSIS 140
  • 17.13.3 PRODUCT PORTFOLIO 141
  • 17.13.4 RECENT DEVELOPMENT 141
• 17.14 MESOBLAST LTD (2021) 142
  • 17.14.1 COMPANY SNAPSHOT 142
  • 17.14.2 REVENUE ANALYSIS 142
  • 17.14.3 PRODUCT PORTFOLIO 143
  • 17.14.4 RECENT DEVELOPMENTS 143
• 17.15 PLURISTEM INC.(2021) 144
  • 17.15.1 COMPANY SNAPSHOT 144
  • 17.15.2 REVENUE ANALYSIS 144
  • 17.15.3 PRODUCT PORTFOLIO 145
  • 17.15.4 RECENT DEVELOPMENT 145
• 17.16 STEMPEUTICS RESEARCH PVT LTD 146
  • 17.16.1 COMPANY SNAPSHOT 146
  • 17.16.2 PRODUCT PORTFOLIO 146
  • 17.16.3 RECENT DEVELOPMENTS 146

• 17.17 U.S. STEM CELL, INC. (2021) 148
  • 17.17.1 COMPANY SNAPSHOT 148
  • 17.17.2 REVENUE ANALYSIS 148
  • 17.17.3 PRODUCT PORTFOLIO 149
  • 17.17.4 RECENT DEVELOPMENT 149

18 QUESTIONNAIRE 150

19 RELATED REPORTS 153

LIST OF TABLES

• TABLE 1 ASIA PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 59
• TABLE 2 ASIA PACIFIC BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 60
• TABLE 3 ASIA PACIFIC PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 61
• TABLE 4 ASIA PACIFIC ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 62
• TABLE 5 ASIA PACIFIC OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 63
• TABLE 6 ASIA PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 67
• TABLE 7 ASIA PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 68
• TABLE 8 ASIA PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 69
• TABLE 9 ASIA PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 70
• TABLE 10 ASIA PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 70
• TABLE 11 ASIA PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 75
• TABLE 12 ASIA PACIFIC MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 76
• TABLE 13 ASIA PACIFIC WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 77
• TABLE 14 ASIA PACIFIC ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
• TABLE 15 ASIA PACIFIC SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
• TABLE 16 ASIA PACIFIC GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 79
• TABLE 17 ASIA PACIFIC CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 80
• TABLE 18 ASIA PACIFIC OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 81
• TABLE 19 ASIA PACIFIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 85
• TABLE 20 ASIA PACIFIC HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 86
• TABLE 21 ASIA PACIFIC THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 87
• TABLE 22 ASIA PACIFIC SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
• TABLE 23 ASIA PACIFIC OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
• TABLE 24 ASIA PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 93
• TABLE 25 ASIA PACIFIC DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 94
• TABLE 26 ASIA PACIFIC THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 95
• TABLE 27 SIA-PACIFIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 101
• TABLE 28 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 101
• TABLE 29 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 101
• TABLE 30 ASIA-PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 101
• TABLE 31 ASIA-PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 102
• TABLE 32 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 102
• TABLE 33 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 102
• TABLE 34 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 102
• TABLE 35 SOUTH KOREA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 103
• TABLE 36 SOUTH KOREA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
• TABLE 37 SOUTH KOREA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
• TABLE 38 SOUTH KOREA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
• TABLE 39 SOUTH KOREA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 104
• TABLE 40 SOUTH KOREA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 104
• TABLE 41 SOUTH KOREA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 104
• TABLE 42 JAPAN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 105
• TABLE 43 JAPAN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 105
• TABLE 44 JAPAN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 105
• TABLE 45 JAPAN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 105
• TABLE 46 JAPAN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 106
• TABLE 47 JAPAN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 106
• TABLE 48 JAPAN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 106
• TABLE 49 INDIA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 107
• TABLE 50 INDIA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 107
• TABLE 51 INDIA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 107
• TABLE 52 INDIA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 107
• TABLE 53 INDIA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 108
• TABLE 54 INDIA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 108
• TABLE 55 INDIA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 108

LIST OF FIGURES

• FIGURE 1 ASIA PACIFIC STEM CELL THERAPY MARKET : SEGMENTATION 18
• FIGURE 2 ASIA PACIFIC STEM CELL THERAPY MARKET: DATA TRIANGULATION 21
• FIGURE 3 ASIA PACIFIC STEM CELL THERAPY MARKET: DROC ANALYSIS 22
• FIGURE 4 ASIA PACIFIC STEM CELL THERAPY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 23
• FIGURE 5 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS 23
• FIGURE 6 ASIA PACIFIC STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS 24
• FIGURE 7 ASIA PACIFIC STEM CELL THERAPY MARKET: DBMR POSITION GRID 26
• FIGURE 8 ASIA PACIFIC STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS 28
• FIGURE 9 ASIA PACIFIC STEM CELL THERAPY MARKET: END USER COVERAGE GRID 29
• FIGURE 10 ASIA PACIFIC STEM CELL THERAPY MARKET: SEGMENTATION 33
• FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 34
• FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE ASIA PACIFIC STEM CELL THERAPY MARKET FROM 2022 TO 2029 35
• FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC STEM CELL THERAPY MARKET FROM 2022 & 2029 35
• FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC STEM CELL THERAPY MARKET 44
• FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022 45
• FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020 46
• FIGURE 17 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021 56
• FIGURE 18 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 57
• FIGURE 19 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 57
• FIGURE 20 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 58
• FIGURE 21 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, 2021 64
• FIGURE 22 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION) 65
• FIGURE 23 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029) 65
• FIGURE 24 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE 66
• FIGURE 25 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, 2021 72
• FIGURE 26 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 73
• FIGURE 27 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029) 73
• FIGURE 28 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE 74
• FIGURE 29 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, 2021 82
• FIGURE 30 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION) 83
• FIGURE 31 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029) 83
• FIGURE 32 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE 84
• FIGURE 33 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021 90
• FIGURE 34 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 91
• FIGURE 35 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 91
• FIGURE 36 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 92
• FIGURE 37 ASIA-PACIFIC STEM CELL THERAPY MARKET: SNAPSHOT (2021) 97
• FIGURE 38 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2021) 98
• FIGURE 39 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029) 98
• FIGURE 40 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029) 99
• FIGURE 41 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022 & 2029) 99
• FIGURE 42 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%) 108